Booster began

Bionovo Inc.
(Nasdaq: BNVI) announced results from a second continuing clinical misery
of BZL101, an oral drug possibility, in patients with refractory, metastatic
breast cancer. The data, which were presented at the American Society of
Clinical Oncology 44th Annual Meeting, showed that BZL101, at higher doses,
continues to press a favorable safety and tolerability silhouette and shows
ongoing attest of clinical activity in women with advanced breast cancer.

“We are encouraged by the positive results of this second study which
further underscores BZL101’s safety at higher doses and highlights its
potential as an effective, novel, vocal treatment payment the more than 45,000
women who are diagnosed with this late stage knocker cancer each year,” said
hero author, Dr. Alejandra Perez, Director of the Breast Cancer Center at
the Memorial Regional Hospital Cancer Institute. “While safeness and superlative
tolerability are the primary endpoints of the venture, BZL101 also showed
prehistoric clinical efficacy, including one compliant who has been stable for 13
months and shows radiographic evidence of tumor shrinkage.”

The study is being conducted by investigators at Duke University,
Columbia Presbyterian Medical Center, University of Chicago, University of
Texas Southwestern Medical Center, Ohio State University, Montefiore
Medical Center, Cancer Experiment with Network and Memorial Regional Cancer
League in collaboration with scientists at Bionovo. The inspect is a Facet
1/2 trial, and is currently in the Phase 1 Dosage Escalation component, and
is expected to progress to the Phase 2 component and full recruitment
during the third phase of the moon of this year.

“Based on the auspicious materials from the early clinical trials of BZL101,
we are excited to metamorphosis to our FDA-approved Moment 2 program later this
year,” said Isaac Cohen, Bionovo’s Chairman and Chief Executive Officer. “I
hold this trial’s results other validate the potential for a novel,
oral anticancer drug with a unique instrument of action that selectively
target cancer cells without affecting sane cells as evidenced by our limited
toxicity and early clinical efficacy. Due to BZL101’s favorable results to
date, Bionovo will consider studying BZL101 as the oldest non-hormonal, spoken
adjuvant for early breast cancer.”

Research Forge and Results

In this open-label, administer escalation trial, 20 patients with
histologically confirmed metastatic breast cancer and measurable illness
were treated with spoken BZL101 until blight progression or toxicity. Mean
ripen was 60 years and patients had failed an average of 3.1 until
chemotherapy treatment regimens since diagnosis with metastatic breast
cancer. Primary endpoints of the scrutiny include safety, toxicity and tumor
response as defined by RECIST (Response Evaluation Criteria In Solid
Tumors), a set of published criteria that discover when a tumor responds,
remains sure or progresses.

The trial is currently ongoing and three different doses of BZL101 have
been found to be coffer and well tolerated. A fourth group of patients is
currently being enrolled to the nuisance in order to find out the maximum
tolerated administer that will be tested in the Phase 2 clinical trial later this
year. There were no serious adverse events (SAEs) associated with BZL101
treatment. Patients were masterly to tolerate BZL101 remedy well and
compliance with treatment was 93% of prescribed doses. The most frequently
reported BZL101-interrelated adverse events were: diarrhea (40%), nausea (30%),
headache (20%), and increased amino alanine transferase (20%).

Twelve patients were evaluable for rejoinder according to RECIST. Five
of the 12 patients had stable disease (SD) during >90 days (42%) and individual
acquiescent, currently on study, has had SD for >170 days. An additional
forbearing has been stable seeking 13 months and had radiographic evidence of
tumor shrinkage.

Up BZL101

BZL101 is an word-of-mouth treatment designed on the side of the treatment of boob cancer that
targets only cancer cells, leaving the normal cells intact and functioning.
BZL101 is an aqueous extract from herba Scutellaria Barbata D. Don of the
Lamiaceae children. BZL101 is a compound that induces cubicle death due to
attenuation of mitochondrial transmembrane aptitude (MTP) leading to the
deliver of reactive oxygen species, causing inhibition of glycolysis and
ending with induction of DNA damage and cell death. There are currently no
effective curative cures for advanced breast cancer and treatment is
initially aimed at palliation of symptoms as through as improving overall
survival. Breast cancer is the second leading reason of cancer death with
approximately 200,000 new cases per year. Although survival after breast
cancer treatments is improving, there are up till more than 40,000 deaths per
year right to tit cancer.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and
development of repository and operational treatments in requital for women’s health and cancer,
markets with significant unmet needs and billions in potential annual
revenue. The following applies its knowledge in the biology of menopause and
cancer to diagram stylish drugs derived from botanical sources which have story
mechanisms of action. Based on the results of early and mid-stage clinical
trials, Bionovo believes they organize discovered up to date classes of knock out
candidates within their rich in the offing with the potential to be leaders in
their markets. Bionovo is headquartered in Emeryville, California and is
traded on the NASDAQ Capital Market junior to the symbol, “BNVI”. Concerning more
poop with regard to Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This distribute contains certain forward-looking statements relating to
the business of Bionovo, Inc. that can be identified by the use of
forward-looking terminology such as “believes,” “expects,” or similar
expressions. Such impertinent-looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to product
advance, efficacy and cover, regulatory actions or delays, the ability
to obtain or maintain obvious or other proprietary intellectual property
care, market acceptance, physician acceptance, third set
reimbursement, later capital requirements, match in general and
other factors that may provoke actual results to be at bottom different from
those described herein as anticipated, believed, estimated or expected.
Certain of these risks and uncertainties are or see fit be described in
greater detail in our filings with the Securities and Exchange Commission,
which are elbow at http://www.sec.gov. Bionovo, Inc. is under no
obligation (and expressly disclaims any such obligation) to update or alter
its impertinent-looking statements whether as a come about of new tidings,
future events or in another manner.

Bionovo Inc.
http://www.bionovo.com